OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.
RBX2660 could make a major difference in treating recurrent Clostridioides difficile infections (rCDI).
Similar to how fecal microbiota transplantation (FMT) is a viable treatment, RBX2660 is a standardized, stabilized, investigational microbiota-based live therapeutic.
In data presented at the 2021 American College of Gastroenterology (ACG) Annual Meeting, investigators found high clinical efficacy in reducing rCDI with a sustained clinical response up to 6 months, with consistent safety results from previous clinical trials.
In the new trial, 94 patients were examined from 5 sites between November 2015 and September 2019, 64 of which were in the primary safety set with a treatment success rate of 82.8% (n = 53). There was no different between patients who received 1 dose (83.3%; n = 20) compared to 2 doses (82.5%; n = 33).
For the patients who initially responded, 88.7% ( n = 47) sustained a clinical response at 6 months.
For safety, 92.2% of the adverse events reported were deemed mild or moderate in severity, including in patients with immune-mediated or autoimmune disorders and non-specific inflammation conditions.
In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained how RBX2660 leverages new technology and why that could be an answer in treating C difficile infections.